ClinicalTrials.gg
RecruitingNCT05971394Updated Aug 2, 2023

IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical Trial

An interventional study of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in Infrapopliteal Lesions and Critical Limb Ischemia, sponsored by Biotyx Medical (Shenzhen) Co., Ltd.. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-08-02.

Sponsored by Biotyx Medical (Shenzhen) Co., Ltd. (part of LifeTech Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy — 5 open to participants now, 5 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Italy.

Planned enrollment
6th of 14
100 · median 65
Started
2023
the only one that year
No phase
8 of 24
2 open now
Registered
21st of 24
by date
Lead sponsor
1 of 24
Biotyx Medical (Shenzhen) Co., Ltd.

Among the 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy, this one is the 6th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 8 with no phase, and was the 21st registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

5 of the 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Chronic Limb-Threatening Ischemia with a site in Italy, or all of them as a file.
02

Study summary

The goal of this prospective, multicentre, single arm clinical trial is to assess the safety and effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in treating patients with infrapopliteal arterial stenosis or occlusive disease. 100 participants will be implanted with IBS Titan™, and be followed up for 1-month, 6-month and 12-month after discharge.

03

Conditions studied

  • Infrapopliteal Lesions
  • Critical Limb Ischemia

Keywords

  • BTK
  • below-the-knee
  • Infrapopliteal lesions
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General criteria
  1. Subject between 18 and 85 years old.
  2. Subject who can understand the purpose of the trial, voluntarily participate in, and sign the form, and who are willing to participate until the 12 months follow-up.
  3. Subject has symptomatic Critical Limb Ischemia, Rutherford category 3-5.
  4. Subject requires primary treatment of de novo infrapopliteal lesions.

    • Angiographic criteria
  5. Target lesion stenosis ≥ 70% or occlusion in no more than two infrapopliteal arteries.
  6. The distal margin of the target lesion must be located ≥ 10 cm proximal to the proximal margin of the ankle mortise.
  7. The target lesion must be located in the proximal 2/3 of native infrapopliteal vessels, length is ≤ 200mm, with vessel diameter of 2.5-4 mm.
  8. Only two infrapopliteal vessels are allowed to be treated at the same time.
  9. A maximum of two stents can be deployed at one target vessel.
  10. There must be at least one unimpaired artery (\< 30% stenosis) to the ankle.

Exclusion criteria

Exclusion Criteria:

  • General criteria:
  1. Severe renal insufficiency, hepatic dysfunction (Cr > 2 times normal limit or renal dialysis, or AST > 5 times normal limit).
  2. Major amputation before index procedure or plan for major amputation.
  3. Any coagulation disorder.
  4. Lower extremity arteries surgery or thrombolytic therapy in the ipsilateral extremity in the past 6 weeks.
  5. Stroke within 3 months, or stroke with severe hemiplegia and aphasia sequelae more than 3 months before inclusion in the study.
  6. Acute myocardial infarction or acute ischemia within 30 days before inclusion in the study.
  7. Thromboangiitis obliterans (Buerger's disease).
  8. Any previous treatment with drug eluting balloon or drug eluting stent within 90 days before inclusion.
  9. Any surgery in target vessel before index procedure.
  10. Volume reduction operation in target vessel before inclusion.
  11. Subject known to be allergic to aspirin, heparin, clopidogrel, Polylactic acid, iron, zinc and its degradation products, contrast agents, sirolimus, etc., and those who cannot tolerate postoperative dual anti- therapy.
  12. Subject with a history of iron overload or iron disorders related diseases, such as hereditary hemochromatosis, etc.
  13. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.
  14. Women of not using an effective ; pregnant or lactating women.
  15. Subject is not suitable to participate in the trial as per investigators discretion.
  16. ≤ 12 months as per investigators judgement.

    • Angiographic criteria
  17. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has lumen stenosis >30% with or without intervention.
  18. The inflow tract (including ipsilateral iliac artery, femoral artery, popliteal artery) has > 150 mm stenosis or occlusion before treatment.
  19. Significant stenosis (≥50% stenosis) of the arterial outflow tract perfused by the target vessel.
  20. In-stent restenosis in any lower extremity artery.
  21. Thrombosis in target vessel, or acute thrombosis requiring thrombolysis and thrombectomy.
  22. Guide wire cannot pass target lesion.
  23. Angiography suggests intraoperative thromboendarterectomy, percutaneous transluminal rotational atherectomy or laser therapy are needed.
  24. Aneurysm of lower extremity artery in the ipsilateral leg.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    IBS Titan

    Subjects treated with IBS Titan™.Participants will be included in this arm.

    Device: Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)

Interventions

  • DeviceSirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)

    Subjects in this arm will be treated with Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)

06

What researchers measure

Primary outcomes

  1. Freedom from Primary Efficacy Failure

    Defined as freedom from the composite of total occlusion of target lesion and clinically driven target lesion revascularization (CD-TLR), and freedom from major amputation.

    Time frame: 6 months

Secondary outcomes

  1. Major adverse event (MAE)

    Defined as a composite of all-cause mortality, CD-TLR and major amputation of target limb.

    Time frame: 1 month, 6 months, 12 months

  2. Rate of Device success

    Stent level analysis, based on single stent. Defined as the achievement of successful delivery, deployment of stent at the intended infrapopliteal target site(s) and successful withdrawal of the delivery catheter.

    Time frame: Immediately post-procedure

  3. Rate of Technical success

    Defined as the restoration of blood flow in the target vessel and angiogram indicates the residual stenosis \<30%.

    Time frame: Immediately post-procedure

  4. Rate of Procedural success

    Defined as the combination of technical success, device success, and absence of procedural complications.

    Time frame: Immediately post-procedure

  5. Incidence of Target lesion restenosis

    Defined as peak systolic velocity ratio (PSVR) \>2.4 by DUS.

    Time frame: 1 month, 6 months, 12 months

  6. Change in ankle-brachial index (ABI) compared to baseline (before treatment)

    Change in Ankle Brachial Index (ABI) from pre-procedure. Larger values mean a better outcome. The ABI is the systolic pressure at the ankle, divided by the systolic pressure at the arm.

    Time frame: 1 month, 6 months, 12 months

  7. Change in Rutherford Category compared to baseline (before treatment)

    Categories and Clinical Description (higher scores mean a worse outcome): Category 0 = Asymptomatic, no hemodynamically significant occlusive disease, Category 1 = Mild claudication, Category 2 = Moderate claudication, Category 3 = Severe claudication, Category 4 = Ischemic rest pain, Category 5 = Minor tissue loss, non-healing ulcer, or focal gangrene with diffuse pedal ischemia, Category 6 = Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable.

    Time frame: 1 month, 6 months, 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jan 2026, 30 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2023
First posted
Aug 2, 2023
StartActual
Jul 17, 2023
Primary completionEst.
Jan 2026
CompletionEst.
Jul 2026
Last update
Aug 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05971394
Collaborators
VascuScience GmbH, Mediolanum Cardio Research Srl, Euroimage Research Srl
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Jul 17, 2023
Primary completion
Jan 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Aug 2, 2023

Study contacts

Ying Xia
Contact
xiaying@lifetechmed.com
0755 23221096

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion